{"Clinical Trial ID": "NCT00568022", "Intervention": ["INTERVENTION 1:", "Ixabepilone 32 mg/m^2 + Capecitabine 1650 mg/m^2/J", "Ixabepilone 32 mg/m^2 was administered by intravenous infusion (IV) for 3 hours on day 1 of each 21-day treatment cycle. Capecitabine 1650 mg/m^2/day was administered on days 1 to 14 of each 21-day treatment cycle.", "INTERVENTION 2:", "Ixabepilone 40 mg/m^2 + Capecitabine 1650 mg/m^2/J", "Ixabepilone 40 mg/m^2 was administered by intravenous infusion (IV) for 3 hours on day 1 of each 21-day treatment cycle. Capecitabine 1650 mg/m^2/day was administered on days 1 to 14 of each 21-day treatment cycle."], "Eligibility": ["Incorporation criteria:", "Women 20 years of age", "A histologically or cytologically confirmed diagnosis of adenocarcinoma from the breast", "- Exclusion criteria:", "Number of previous chemotherapy treatment lines in the metastatic setting 3"], "Results": ["Performance measures:", "Participants with a Toxic Limit Dose (DLT)", "DLT has been defined as any event related to ixabepilone and/or capecitabine requiring discontinuation of the study during the first two treatment cycles.", "Time limit: From the initiation of the medicine to the last day of cycle 2 (Day 42)", "Results 1:", "Ixabepilone 32 mg/m^2 + Capecitabine 1650 mg/m^2/J", "Ixabepilone 32 mg/m^2 was administered by intravenous infusion (IV) for 3 hours on day 1 of each 21-day treatment cycle. Capecitabine 1650 mg/m^2/day was administered on days 1 to 14 of each 21-day treatment cycle.", "Total number of participants analysed: 3", "Type of measurement: Number", "Unit of measure: Participants 0", "Results 2:", "Ixabepilone 40 mg/m^2 + Capecitabine 1650 mg/m^2/J", "Ixabepilone 40 mg/m^2 was administered by intravenous infusion (IV) for 3 hours on day 1 of each 21-day treatment cycle. Capecitabine 1650 mg/m^2/day was administered on days 1 to 14 of each 21-day treatment cycle.", "Total number of participants analysed: 3", "Type of measurement: Number", "Unit of measure: Participants 0"], "Adverse Events": ["Undesirable Events 1:", "Total: 0/3 (0.00 per cent)", "NEUTROPENIA 0/3 (0.00 %)", "SKIN INFECTION 0/3 (0.00 %)", "Adverse Events 2:", "Total: 1/3 (33.33 per cent)", "NEUTROPENIA 0/3 (0.00 %)", "SKIN INFECTION 1/3 (33.33%)"]}